SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as community members discuss its potential link to ExxonMobil's carbon capture technology for powering data centers, sparking optimism for the stock's future. The stock's recent surge in trading volume and price has investors comparing it to sector peer Bloom Energy, while analyzing options activity and potential news catalysts. Despite past performance concerns, some believe FuelCell is now well-positioned to capitalize on increasing demand for clean and reliable energy solutions.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to a potential bidding war between Novo Nordisk and Pfizer to acquire the company and its obesity drug pipeline, with Pfizer even filing a lawsuit related to the offers. Community members are discussing whether Pfizer will increase its bid or if another company like Eli Lilly could enter the competition. The surge in interest is also fueled by recent data, though some debate the drug's efficacy and side effect profile compared to competitors.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

Ucore Rare Metals is trending due to recent Canadian government funding approval for its rare earth processing facility, considered a de-risking event for the Capex-heavy OTC stock. The community is discussing potential short squeezes and the company's recession-resistant qualities given government backing and national security implications. Some investors are drawing comparisons to other stocks while expressing excitement for potential gains, viewing Ucore as strategically positioned in the rare earth element sector.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy ($PRO) is trending due to discussions around potential pumps and dumps, with community members actively debating price movements and trading strategies. The coin's association with Real World Assets (RWAs) and real estate transactions is also a prominent talking point. Some traders are expressing frustration with price volatility, while others remain bullish on its long-term potential.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWXT is trending as the community discusses its strong position in the nuclear sector and potential benefits from increased demand for nuclear energy, especially with the rise of AI and data centers. Some investors are drawing comparisons between BWXT and Nvidia, suggesting that BWXT could become a key player in the nuclear energy space similar to Nvidia's role in AI. High institutional ownership and government contracts are also being noted as potential drivers for growth.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as the community discusses its potential role in AI-driven identity verification, especially following news of partnerships and treasury initiatives centered around WLD. Community members are weighing the long-term outlook and speculating on integration with projects like OpenAI, while some are closely monitoring price movements and key levels. The broader conversation includes discussion around the need for proof-of-humanity solutions in the face of increasing AI development.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a significant price increase and higher than average trading volume, sparking community discussion about potential catalysts. Some speculate on a possible buyout, while others express concerns about past stock performance and the impact of opinions from individuals in the FDA. Upcoming presentations of new data on LUPKYNIS may also be influencing the stock's movement.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors anticipate the upcoming Q3 financial results, with community chatter focusing on revenue and EPS expectations, and the potential for a double-digit swing in stock price based on the results. Discussions also include Briumvi's market position against competitors like Kesimpta and potential impacts from a Neuraxpharm sale, while some traders are eyeing potential buyout scenarios.

YPF SA engages in the exploration, production, and distribution of oil and gas. It operates through the following segments: Upstream, Gas and Power, Downstream, Central Administration and Other. The Upstream segment sells petroleum and natural gas. The Gas and Power segment markets natural gas to third parties and downstream segment; and manages commercial and technical LNG Regasification Terminals in Bahia Blanca and Escobar. The Downstream segment produces petroleum refining and petrochemicals. The Central Administration and Other segment covers corporate administrative expenses and assets, construction activities, and the environmental remediation. The company was founded on June 2, 1977 and is headquartered in Buenos Aires, Argentina.

YPF - ADR

YPF S.A.

YPF is trending as community members discuss potential privatization following recent political developments in Argentina. Bullish sentiment is fueled by expectations of economic reform and increased focus on cash generation, though some caution against overblown hype and note existing debt. Discussions also involve technical analysis, options activity, and potential price targets.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending amidst community debate about its price action and potential. Some investors express frustration over recent declines and accuse the coin of being a "shitcoin" or "scam", while others remain optimistic, citing upcoming developments like the Goliath mainnet launch and staking rewards. Technical analysis and comparisons to other cryptocurrencies are also being discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sinovac Biotech saw a sharp uptick in retail investor interest late Sunday after the company disclosed a legal win that paves the way for a $55 per share special cash dividend, payable on July 7.The U.S. District Court for the Southern District of New York denied a petition for emergency injunctive relief filed by Advantech/Prime Success, a member of the so-called “Dissenting Investor Group” that includes Vivo Capital.&nbsp;The group had sought to block the current board from executing the dividend payout, which follows a broader dispute over corporate control and the legitimacy of prior board actions.The court ruling clears a major legal obstacle for the current Sinovac Board, which was installed following a Privy Council order and proceedings under Antiguan law.&nbsp;The board now has a clear path to disburse the $55 dividend through its designated paying agent.In a statement, Sinovac said that if it succeeds in separate legal proceedings in Antigua to cancel disputed Private Investment in Public Equity (PIPE) shares issued by the previous board, it intends to distribute an additional $11 per share to valid shareholders.Sinovac accused the dissenting group of deploying “multi-pronged lawfare” to prevent valid shareholders from receiving dividends unless PIPE shares, which the current board deems invalid, were included.&nbsp;According to Sinovac, over $1 billion has already been paid to the dissenting group via a Sinovac operating unit.The board has placed the pro rata portion of dividend funds for disputed PIPE shares in escrow, pending the outcome of the ongoing litigation.In parallel, Sinovac is preparing for a special shareholder meeting on July 8, at which investors will vote on two proposals to replace the current board.&nbsp;The company urged shareholders to vote “against” both proposals and to support the existing leadership.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.Sinovac’s shares remain halted from trading on Nasdaq and have not changed hands since February 2019.&nbsp;The trading suspension followed prolonged governance disputes, including contested PIPE share issuances and competing board claims.&nbsp;Although recent court rulings have favored the current board and cleared the way for a planned dividend payout, the company has not announced a timeline for resuming trading or disclosed whether it has met Nasdaq’s requirements for relisting.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Chinese Sinovac vaccine for Covid-19 logo seen displayed on a smartphone. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Sinovac Clears Legal Hurdle In Control Battle, Moves Forward With $55 Dividend 

A U.S. court denied an emergency injunction sought by dissenting investors, while a separate case in Antigua could unlock an additional $11 per share if disputed PIPE shares are invalidated.

Equity

SINOVAC Issues Statement Regarding Privy Council Judgment

Sinovac Biotech Ltd. (NASDAQ:SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London...

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine...

SINOVAC Reports Unaudited First Half of 2024 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June...

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and...

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (Sinovac or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights...

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the Board of Directors...

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Sinovac Biotech, Ltd.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$6.47
Prev Close	$6.49
Open	$6.47
Dividend Yield	N/A
50-Day Moving Average	$6.47
Beta	0.00
Avg. Volume	0.00
PE Ratio	N/A

52-Week High	$6.47
52-Week Low	$6.47
Market Capitalization	$464.94M
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

SVA
Sinovac Biotech, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SVA News

SVASinovac Biotech, Ltd.